Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Chowdhury

Showing results (71-80 of 151) with videos related to

Pageof 16
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 7, 2024
Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trialSoumyajit Roy, Fred Saad, Yilun Sun, et al.
BJU International|February 3, 2015
Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279)Amit Bahl, Susan Masson, Zafar Malik, et al.
World Journal of Urology|September 22, 2018
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancerAxel S Merseburger, Andrea B Apolo, Simon Chowdhury, et al.
European Urology Open Science|November 10, 2022
Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer RegistryAnders Bjartell, Luis Costa, Gero Kramer, et al.
European Urology|December 17, 2021
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTANFred Saad, Eric J Small, Felix Y Feng, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2014
A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancerThomas Powles, Shah-Jalal Sarker Foreshew, Jonathan Shamash, et al.
Cancer Medicine|January 31, 2023
Accurate prostate cancer detection based on enrichment and characterization of prostate cancer specific circulating tumor cellsSewanti Limaye, Simon Chowdhury, Nitesh Rohatgi, et al.
BMJ Open|September 28, 2019
Graham Roberts Study protocol: first 'trials within cohort study' for bladder cancerHarriet Wylie, Fidelma Cahill, Aida Santaolalla, et al.
BJU International|January 20, 2011
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysisDebra Josephs, Thomas E Hutson, Charles L Cowey, et al.
JAMA Oncology|June 3, 2021
Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate CancerFelix Y Feng, Shibu Thomas, Fred Saad, et al.
Pageof 16

Showing results (71-80 of 151) with videos related to

Sort By:
Pageof 16
European Journal of Cancer (Oxford, England : 1990)|September 7, 2024
Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trialSoumyajit Roy, Fred Saad, Yilun Sun, et al.
BJU International|February 3, 2015
Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279)Amit Bahl, Susan Masson, Zafar Malik, et al.
World Journal of Urology|September 22, 2018
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancerAxel S Merseburger, Andrea B Apolo, Simon Chowdhury, et al.
European Urology Open Science|November 10, 2022
Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer RegistryAnders Bjartell, Luis Costa, Gero Kramer, et al.
European Urology|December 17, 2021
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTANFred Saad, Eric J Small, Felix Y Feng, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2014
A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancerThomas Powles, Shah-Jalal Sarker Foreshew, Jonathan Shamash, et al.
Cancer Medicine|January 31, 2023
Accurate prostate cancer detection based on enrichment and characterization of prostate cancer specific circulating tumor cellsSewanti Limaye, Simon Chowdhury, Nitesh Rohatgi, et al.
BMJ Open|September 28, 2019
Graham Roberts Study protocol: first 'trials within cohort study' for bladder cancerHarriet Wylie, Fidelma Cahill, Aida Santaolalla, et al.
BJU International|January 20, 2011
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysisDebra Josephs, Thomas E Hutson, Charles L Cowey, et al.
JAMA Oncology|June 3, 2021
Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate CancerFelix Y Feng, Shibu Thomas, Fred Saad, et al.
Pageof 16